Amneal Pharmaceuticals, Inc.
AMRX
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmiā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$13.20
Price-0.45%
-$0.06
1Y
Price
Market Cap
$4.150b
Mid
Price/Earnings 3y Avg5y Avg
1,320x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+14.2%
EBITDA Margin+0.3%
Net Profit Margin+13.2%
Free Cash Flow Margin+14.2%
EBITDA Margin+0.3%
Net Profit Margin+13.2%
Free Cash Flow MarginRevenue
$2.935b
+5.1%
1y CAGR+10.0%
3y CAGR+8.9%
5y CAGREarnings
$5.900m
+105.1%
1y CAGR+33.8%
3y CAGR-305.6%
5y CAGREPS
$0.01
+102.6%
1y CAGR+55.9%
3y CAGR-290.2%
5y CAGRBook Value
-$109.955m
$3.600b
Assets$3.710b
Liabilities$2.686b
DebtDebt to Assets
74.6%
4.8x
Debt to EBITDAFree Cash Flow
$244.817m
+11.2%
1y CAGR+391.7%
3y CAGR+265.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company